Skip to main content
Erschienen in: Neurological Sciences 1/2013

01.05.2013 | SYMPOSIUM – BOTULINUMTOXINA (ALLERGAN) AND CHRONIC MIGRAINE: FROM TRIAL TO CLINICAL PRACTICE

Onabotulinum toxin A for treatment of chronic migraine with medication overuse

verfasst von: L. Grazzi

Erschienen in: Neurological Sciences | Sonderheft 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.
Literatur
1.
Zurück zum Zitat Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRef Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRef
2.
Zurück zum Zitat Grazzi L, Andrasik F, Usai S, Bussone G (2009) Treatment of chronic migraine with medication overuse: is drug withdrawal crucial? Neurol Sci 30(S1):85–88CrossRef Grazzi L, Andrasik F, Usai S, Bussone G (2009) Treatment of chronic migraine with medication overuse: is drug withdrawal crucial? Neurol Sci 30(S1):85–88CrossRef
3.
Zurück zum Zitat Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008(64):274–283CrossRef Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008(64):274–283CrossRef
4.
Zurück zum Zitat Mathew N, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache. A randomized, double blind, placebo controlled trial. Headache 45:293–307PubMedCrossRef Mathew N, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache. A randomized, double blind, placebo controlled trial. Headache 45:293–307PubMedCrossRef
5.
Zurück zum Zitat Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylaxis treatment of medication-overuse headache: a multi center, double blind, randomized, placebo-controlled, parallel group study. J Head pain 12:427–433CrossRef Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylaxis treatment of medication-overuse headache: a multi center, double blind, randomized, placebo-controlled, parallel group study. J Head pain 12:427–433CrossRef
6.
Zurück zum Zitat Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of Onabotulinum toxin A for chronic migraine: a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418PubMedCrossRef Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of Onabotulinum toxin A for chronic migraine: a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418PubMedCrossRef
7.
Zurück zum Zitat Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793PubMedCrossRef Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793PubMedCrossRef
8.
Zurück zum Zitat Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15PubMedCrossRef Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15PubMedCrossRef
9.
Zurück zum Zitat Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–69PubMedCrossRef Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–69PubMedCrossRef
10.
Zurück zum Zitat Headache Classification Subcommittee of the International Headache Society (2004) The International classification of headache disorders-2nd edition. Cephalalgia 24(suppl 1):1–160 Headache Classification Subcommittee of the International Headache Society (2004) The International classification of headache disorders-2nd edition. Cephalalgia 24(suppl 1):1–160
11.
Zurück zum Zitat Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Goebel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRef Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Goebel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRef
Metadaten
Titel
Onabotulinum toxin A for treatment of chronic migraine with medication overuse
verfasst von
L. Grazzi
Publikationsdatum
01.05.2013
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2013
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1381-1

Weitere Artikel der Sonderheft 1/2013

Neurological Sciences 1/2013 Zur Ausgabe

MIGRAINE: A DISORDER OF THE BRAIN

Sensitization and pain

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.